VetusLignum wrote:You can always be ironic, the interest of blood thinners on patients with respiratory problems is well known. For example :
https://lactualite.com/actualites/covid ... -patients/
For my part, what I observe is that although you have been on this thread for weeks, you give the feeling of having understood nothing from the start; we're still explaining the basics to you.
So, in some cases, it may be helpful to respond, thinking of the readers who, indeed, may be a little lost.
But it seems obvious to me (to me as to others), that you are not as silly as you seem, and that if you constantly pretend to understand nothing, it is just to confuse each other and disrupt the discussion.
bah for me the basics in general and independently of the Covid, is that we can not draw firm conclusions on statistics obtained in poorly known conditions and with variability in the sample. You obviously agree with me since you attribute the difference in lethality between HCQ + AZT and HCQ alone (20% versus 13% anyway) to the fact that the samples were different and not because of the treatment.
After you seem to be saying that double-blind studies are not necessary, which I do not understand well since precisely as we have just seen the results cannot be interpreted if the populations are not the same - and the double blind studies it is precisely to ensure that the populations are statistically similar.
I do not see well what is tangled in it since it is what you recognized yourself on the example above.
Unless you don't understand what you are explaining yourself?